Nephrology Products

Highlight

• First Darbepoetin alfa similar
• Improved convenience with once-every-1-to-4 week dosing
• Proven equivalent in efficacy and long-term safety compared to the reference drug

Indication

Anemia associated with chronic kidney disease (CKD) in patients on hemodialysis or not on dialysis.

Specification:

• Form: Solution for injection (prefilled syringe)
• Strength: 20 · 30 · 40 μg
• Pack: Box, 1 prefilled syringe
• REG. BPM: DKI2284401143A1 (20 μg)

Highlight

• Complete Strength of EPO Alfa
• Listed in E-Catalogue
• Local Manufactured

Indication

• Anemia caused by renal insufficiency, including patients with hemodialysis and non-hemodialysis due to chronic renal failure.
• Anemia caused by non-myeloid malignancy applied chemotherapy, other than those with anemia caused by other factors in the treatment of cancer patients (e.g. iron or folate deficiency, hemolysis or intestinal tract bleeding)

Specification:

• Form: Solution for injection (prefilled syringe)
• Strength: 2,000 IU · 3,000 IU · 5,000 IU
• Pack: Box, 1 prefilled syringe
• REG. BPM: DKL2257901243A1 (2,000 IU) · DKL2257901243B1 (3,000 IU) · DKI2046400243C1 (4,000) · DKI2046400243E1 (5,000 IU)
• E-Catalogue: Listed